The Royal Gazette has published an FDA order revoking the registration of a popular herbal capsule product due to false information provided during registration, rendering the herbal product unsafe for consumers.
On 22 January 2026, it was reported that the websiteof the Royal Gazettepublished an order from the Food and Drug Administration (FDA) No. 21/2569 regarding the revocation of one herbal product registration certificate.
The order states that after inspection and analysis, the herbal capsule product "Ginseng Pu Shen" registration number G 427/52 was found to contain modern medicines sildenafil and tadalafil. This classifies the product as partially or wholly an artificial herbal or imitation substance intended to appear as a genuine herbal product, violating Section 59(1). It also falsely represented itself as a registered herbal formula, violating Section 59(5). Therefore, it is considered unsafe for consumers and a counterfeit herbal product under Section 58(1) of the Herbal Products Act B.E. 2562 (2019).
Under the authority of Section 43(3) of the Herbal Products Act B.E. 2562, the FDA Secretary-General, with the approval of the Herbal Product Committee during its 6/2568 meeting on 4 December 2025, issued an order to revoke the registration certificate for the herbal capsule product "Ginseng Pu Shen," registration number G 427/52.
If the holder of the registration certificate disagrees with this order, they may file a lawsuit with the Administrative Court by submitting a written complaint directly or by registered mail to the Central Administrative Court within 90 days from the date of notification of this order.
This order takes effect from the date of its publication in the Royal Gazette onward.
Ordered on 9 January 2026.
Runguthai Muanprasitporn
Deputy Secretary-General of the Food and Drug Administration
Acting Secretary-General of the Food and Drug Administration